These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28199393)

  • 1. Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
    Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A
    PLoS One; 2017; 12(2):e0172640. PubMed ID: 28199393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
    O'Hear C; Heiber JF; Schubert I; Fey G; Geiger TL
    Haematologica; 2015 Mar; 100(3):336-44. PubMed ID: 25480499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy.
    Pizzitola I; Agostoni V; Cribioli E; Pule M; Rousseau R; Finney H; Lawson A; Biondi A; Biagi E; Marin V
    J Immunother; 2011; 34(6):469-79. PubMed ID: 21654519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
    Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
    Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of CD33 as therapeutic target in acute myeloid leukemia.
    Walter RB
    Expert Opin Ther Targets; 2014 Jul; 18(7):715-8. PubMed ID: 24750020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
    Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
    Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction: GATA2 Inhibition Sensitizes Acute Myeloid Leukemia Cells to Chemotherapy.
    Yang L; Sun H; Cao Y; Xuan B; Fan Y; Sheng H; Zhuang W
    PLoS One; 2017; 12(3):e0175005. PubMed ID: 28350881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational CD33-targeted therapeutics for acute myeloid leukemia.
    Walter RB
    Expert Opin Investig Drugs; 2018 Apr; 27(4):339-348. PubMed ID: 29534618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
    Arcangeli S; Rotiroti MC; Bardelli M; Simonelli L; Magnani CF; Biondi A; Biagi E; Tettamanti S; Varani L
    Mol Ther; 2017 Aug; 25(8):1933-1945. PubMed ID: 28479045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
    Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
    Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction.
    Pohlen M; Thoennissen NH; Braess J; Thudium J; Schmid C; Kochanek M; Kreuzer KA; Lebiedz P; Görlich D; Gerth HU; Rohde C; Kessler T; Müller-Tidow C; Stelljes M; Hullerman C; Büchner T; Schlimok G; Hallek M; Waltenberger J; Hiddemann W; Berdel WE; Heilmeier B; Krug U
    PLoS One; 2018; 13(1):e0190802. PubMed ID: 29293694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor.
    Schirrmann T; Pecher G
    Leuk Res; 2005 Mar; 29(3):301-6. PubMed ID: 15661266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of A Chimeric Antigen Receptor Targeting C-Type Lectin-Like Molecule-1 for Human Acute Myeloid Leukemia.
    Laborda E; Mazagova M; Shao S; Wang X; Quirino H; Woods AK; Hampton EN; Rodgers DT; Kim CH; Schultz PG; Young TS
    Int J Mol Sci; 2017 Oct; 18(11):. PubMed ID: 29077054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correction: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615707
    [No Abstract]   [Full Text] [Related]  

  • 15. CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia.
    Bonifant CL; Szoor A; Torres D; Joseph N; Velasquez MP; Iwahori K; Gaikwad A; Nguyen P; Arber C; Song XT; Redell M; Gottschalk S
    Mol Ther; 2016 Sep; 24(9):1615-26. PubMed ID: 27401038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunologic characteristics and prognosis of acute myeloid leukemia M1].
    Zhao F; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):687-91. PubMed ID: 17708783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
    Zhou L; Liu X; Wang X; Sun Z; Song XT
    Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction: Aclacinomycin A Sensitizes K562 Chronic Myeloid Leukemia Cells to Imatinib through p38MAPK-Mediated Erythroid Differentiation.
    Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
    PLoS One; 2017; 12(10):e0186528. PubMed ID: 29020096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias.
    Suggs JL; Cruse JM; Lewis RE
    Exp Mol Pathol; 2007 Dec; 83(3):471-3. PubMed ID: 17963747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction: MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
    Lin TY; Chen KC; Liu HE; Liu AJ; Wang KL; Shih CM
    PLoS One; 2017; 12(3):e0173828. PubMed ID: 28267803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.